Biogen Licenses Immune Drug from Vanqua Bio
Biogen has acquired the rights to an experimental immune system-regulating drug from Vanqua Bio, a biotech company backed by OrbiMed.
The preclinical drug is designed to inhibit "C5aR1", a protein that regulates inflammation and the immune system's response to pathogens and harmful cells.
- Biogen will pay $70 million upfront for exclusive, worldwide rights to the drug.
- Vanqua Bio may receive up to $990 million more, depending on development, regulatory, commercial, and sales goals.
- Vanqua Bio is also eligible for tiered royalties on net sales if the drug comes to market.
Biogen will lead all future development, manufacturing, and commercialization efforts.
No statement from the companies.
Author's summary: Biogen invests over $1 billion in Vanqua Bio's immune drug.